Cantor Fitzgerald issued a new report on Hexo Corp. HEXO HEXO after the company announced the $925 million acquisition of Redecan, Canada’s largest privately-owned licensed producer.
Analyst Pablo Zuanic maintained a Neutral rating but increased the 12-month price target to CA$3.45 ($2.73) from CA$3.40 ($2.70) after tweaking pro forma estimates.
Hexo shares were $2.48 at the time of this writing, mid-afternoon Tuesday.
“We will remain Neutral for now, partly on a legacy of continued dilution, but if over time, all this translates to a profitable cash generating LP (one of the largest, if not the largest), then we think the stock should start to rerate at some point,” Zuanic wrote.
According to the firm’s analysis, key potential drivers for the company going forward are:
- Investors getting a better sense of the scale and prowess of the combined company on an ongoing basis.
- HEXO starting to report positive EBITDA in FY22.
- More visibility about the company’s U.S. strategy.
- Management clearly stating that further stock dilution is unlikely in the year ahead.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.